Institute for Immunity Transplantation and Infection–

Clinical Trials

For a directory of all Stanford Clinical Trials, click HERE.

Cornelia L. Dekker, MD

A Phase I, Randomized, Controlled, Double-Blind, Dosage-Escalation Trial to Evaluate the Immunogenicity, Safety and Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Healthy Adults 18 to 45 Years of Age (DMID 05-0050)

The Stanford-LPCH Vaccine Program is seeking healthy adults for an experimental malaria vaccine study.  Malaria is caused by the Plasmodium parasite and is transmitted from person-to-person through the bite of a female Anopheles mosquito. The disease currently represents one of the most prevalent infections in tropical and subtropical areas causing severe illness in 300 to 500 million individuals worldwide and causing up to three million deaths every year. Most of these deaths occur among children and pregnant women in the developing world, especially in sub-Saharan Africa. Although most people affected with malaria are from the developing world, the disease also affects travelers.
 
Enrolling in this study may help us develop a possible vaccine for this devastating disease by comparing the safety and immune response of varying doses of a malaria vaccine.  The vaccine will be administered to healthy adults by intramuscular injection into the upper arm.
 
Dr. Cornelia L. Dekker, Professor of Pediatrics, will serve as the Principal Investigator for the Stanford-LPCH portion of the trial.  The trial is sponsored by the National Institutes of Health and is taking place at Vanderbilt and Stanford Universities.
 
This study requires a firm commitment from the volunteers, so we recommend that you read carefully through the description of the study and review the eligibility criteria to determine if you would like to participate.
 
If you decide to help us, you will make 16 clinic visits at Stanford Hospital over a 7 – 8 month period.  You also will receive 3 brief phone contacts and additional visits may be required for pregnancy testing.  You will receive three doses of either a malaria vaccine (5 out of 6 chance) or a placebo injection that contains no vaccine (1 out of 6 chance).   A blood sample will be taken at ten of the clinic visits.  After the 16 clinic visits are completed, participants may be contacted by study staff once a year by telephone for an additional four years.  Participants will receive $30.00 reimbursement for each regularly scheduled clinic visit and $60.00 for each vaccination visit that they complete.  There will be no costs for participating in the study and parking vouchers will be given.  If this sounds like a study you might be interested in we strongly encourage you to review the eligibility criteria on our website to see if you can qualify.  Thank you for taking the time to learn more about our study. We look forward to the possibility of working with you, please feel free to contact us if you have any questions.   
ELIGIBILITY: We are enrolling healthy adults who are 18 to 45 years of age.  Interested participants are encouraged to visit our website before deciding on participation.  http://vaccines.stanford.edu/clinical_trials.html
 
FOR MORE INFORMATION:
Please contact the Stanford-LPCH Vaccine Program at (650) 498-7284, email Vaccines_Program at stanford dot edu [Vaccines_Program] or visit our website at   http://vaccines.stanford.edu/clinical_trials.html
 
(For further information regarding your rights as a participant, please call 1-866-680-2906 or write the Administrative Panel on Human Subjects in Medical Research, Administrative Panels Office, Stanford University, Stanford, CA  94305-5401.)

David Fiorentino, MD

Clinical Trial Opportunities in Dermatology

  1. Atopic dermatitis (eczema).  We are soon to enroll participants in a randomized, placebo-controlled trial of a novel oral anti-inflammatory agent.  This trial is approximately 2 months long and involves weekly visits.
  2. Lichen planus.  If you suffer from skin or oral/genital lichen planus, we are currently enrolling participants in a randomized, placebo-controlled trial of etanercept.  This trial is 6 months long, and everybody is guaranteed exposure to active drug during the trial.
  3. Sarcoidosis (primarily skin disease).  We will soon be enrolling participants in an open label trial of adalimumab (humira).  Everybody receives active drug.
  4. Pyoderma gangrenosum.  We will soon be enrolling participants in an open label trial of adalimumab (humira).  Everybody receives active drug.
  5. Pemphigus vulgaris.  We are currently enrolling participants in a randomized, placebo-controlled trial of etanercept.  This trial is 4 months long.
  6. Dermatomyositis/polymyositis.  We are soon to enroll participants in a randomized, placebo-controlled trial of Rituximab.  This trial is one year long and everybody receives active drug at some time during the trial.
  7. Systemic sclerosis (scleroderma).  We will soon begin enrollment for a trial of orencia (CTLA4-Ig).

For more information, call 650-724-3617 or email us at skinstudies at yahoo dot com [skinstudies yahoo.com] .

Emmet Keeffe, MD

Current Trials

Principal Investigator-SUMC: Observational database on patients who receive orthotopic liver transplantation for hepatitis B. National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, RO1 (2001-current).

Principal Investigator-SUMC: Recurrent hepatitis B after liver transplantation. National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, RO1 (2001-current).

Past Trials

Principal Investigator-SUMC: The efficacy of prophylactic interferon and ribavirin combination therapy compared to interferon monotherapy in prevention of recurrent hepatitis C after orthotopic liver transplantation.  Schering (1999).

Principal Investigator-SUMC:  National hereditary hemochromatosis transplant registry: United States national registry. National Institutes of Health, RO3 (1997-2000).

Principal Investigator-SUMC: Recurrent hepatitis B after liver transplantation. National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, RO3 (1998-2001).

JG Montoya, MD

Clinical Trials in Infectious Diseases

<B>Valganciclovir for Chronic Fatigue Syndrome in Patients with Elevated Viral Titers.</B>  PI: JG Montoya, MD   Fellow: AM Kogelnik, MD, PhD.  We are currently enrolling CFS patients who qualify in a double-blind, placebo-controlled trial of valganciclovir - for more information, please contact us at stanfordtrial@hhv-6foundation.org (Please be patient as the response to this study has been overwhelming).
Contact: at hhv dash 6foundation dot org [stanfordtrial hhv-6foundation.org]

Stanford Medicine Resources:

Footer Links: